TAK
$18.39
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
Recent News
KROS: Is the Discount Book Value a Value Trap?
Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.
Assessing Takeda Pharmaceutical (TSE:4502) Valuation After Strong Multi‑Period Shareholder Returns
Recent returns and business profile Takeda Pharmaceutical (TSE:4502) has drawn fresh attention after a period where its share price total return is 0.3% over the past 3 months and 15.4% year to date, set against mixed shorter term moves. Over the past month, the stock shows a 1.1% gain, with a flat 1 day move and a slight 0.2% decline over the past week, while the 1 year total return stands at 33.8% and the 3 year total return at 47.5%. The company reports revenue of ¥4.46b and net income of...
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
DNLI stock jumps as investors eye an April 5, 2026, FDA decision on tividenofusp alfa for Hunter syndrome, a key catalyst for growth.
Actos Class Action Puts Eli Lilly Legal And Cash Flow Risks In Focus
A U.S. court has certified a nationwide class of third party payors in racketeering litigation tied to the diabetes drug Actos. The class includes U.S. insurers and other payors that reimbursed for Actos and related drugs between 1999 and 2010. Eli Lilly (NYSE:LLY) and Takeda face allegations of concealing bladder cancer risks, with potential liability under RICO statutes. Class members are now at a decision point on whether to participate in or opt out of the case. Eli Lilly, trading at...